Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level

NCT01168570 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2010-08-17

No results posted yet for this study

Summary

Purpose of this study is to determine whether keeping SAA on normal or near normal level will delay progression of renal failure in patients with amyloidosis secondary to FMF.

Conditions

  • Observational

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Avi Livneh, MD · Sheba Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2016-09-30
Completion
2017-09-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01168570 on ClinicalTrials.gov